Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yohimbine + hydrocortisone
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A pharmacological combination consisting of yohimbine, an alpha-2-adrenergic receptor antagonist, and hydrocortisone, a glucocorticoid. This combination has been studied for its effects on panic symptoms and attention to social threat cues. Research suggests that hydrocortisone may attenuate the panic symptoms induced by yohimbine. The combination has shown unique effects on attentional bias to emotional stimuli compared to either drug alone.
- Other names
- Active stressorYohimbine hydrochloride + Hydrocortisone
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA2A (α2A)GR (Glucocorticoid receptor)I2R (Imidazoline I2 receptor)
Beyond the preview
Go deeper on yohimbine + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yohimbine + hydrocortisone.